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CD95-Mediated Signals in the Skin: 
Going Out with an (Inflammatory) 
Bang?
Martin Leverkus1 and Axel Trautmann2
The death ligand CD95L (Fas/Apo-1–ligand) has been viewed as a proapoptotic 
molecule involved in the pathogenesis of T cell-mediated skin diseases includ-
ing eczema. In the presence of inhibitors of caspases, CD95L induces proin-
flammatory genes in keratinocytes. This more pleiotropic function of CD95L as 
enhancer of inflammation may be equally important to apoptosis induction of 
keratinocytes, at least in eczema.
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Eczematous dermatitis is not a specific 
disease but rather a common pattern of 
skin inflammation, induced and main-
tained by a variety of environmen-
tal or intrinsic factors such as contact 
allergens, irritants, infective agents, or 
atopy. The clinical features of eczema 
are related to increased blood flow in 
the vessels (erythema), augmented vas-
cular permeability (edema), invasion 
of T cells into the tissue (infiltration), 
epidermal spongiosis (vesiculation), 
and a release of mediators (pruritus). 
During these eczematous diseases, 
the resident structural elements in the 
skin (for example, keratinocytes, fibro-
blasts, endothelial cells) tightly interact 
with cells that are actively recruited 
from the blood in response to inflam-
matory stimuli. A complex interaction 
of numerous chemokines controls the 
recruitment of T cells from the blood 
vessels and their migration into the 
dermis and epidermis (Goebeler et al., 
2001). However, the detailed under-
standing of the morphological changes 
during the effector phase of eczematous 
diseases is still poor, and keratinocytes 
especially are an important and often 
underappreciated participant in this 
cutaneous inflammation. Importantly, 
the eczematous inflammation of the 
epidermo-dermal unit is caused by 
the intricate interaction of T cells and 
keratinocytes with T cell-derived 
inflammatory cytokines, IFNs, and 
other immunoregulatory mediators 
produced by keratinocytes. Thus the 
local response of keratinocytes togeth-
er with the reaction of endothelial 
cells, T cells, mast cells, and dendritic 
cells finally leads to the characteristic 
clinical and histological symptoms of 
eczema. It has been suggested that the 
death ligand Fas/Apo-1 ligand (CD95L; 
see below) expressed on activated 
T cells plays a crucial role in keratino-
cyte death during the elicitation phase 
of eczematous dermatitis (Trautmann 
et al., 2000). However, only single 
keratinocytes undergo apoptosis in 
acute eczema; this supports a concept 
in which the resistance to death ligand-
mediated apoptosis may rather define 
an alternative response of keratinocytes 
to death receptor ligation.
The Fas/Apo-1 (CD95) receptor 
belongs to the death receptor subfamily 
within the tumor necrosis factor (TNF) 
receptor family of transmembrane 
receptors. This subfamily also contains 
TRAIL-R1, TRAIL-R2, DR3, TNF-R1, 
DR6, EDA-R, and NGF-R (Locksley 
et al., 2001). Farley and colleagues 
(2006) have now shed light on CD95 
signaling in the skin by investigating 
extensively which signals are induced 
by CD95 ligation. They first performed 
an unbiased analysis of target genes 
activated by CD95L in cultured HaCaT 
keratinocytes. In line with data for 
another mainly proapoptotic death 
ligand of this group named TNF-relat-
ed apoptosis-inducing ligand (TRAIL) 
(Leverkus et al., 2003a; Wachter et al., 
2004), Farley et al. (2006) demonstrate 
that CD95L efficiently activated a mul-
titude of proinflammatory target genes 
to an extent comparable to that of the 
induction obtained by IL-1β or TNF. 
Interestingly, CD95L-mediated induc-
tion of proinflammatory target genes 
occurred at a later time point when 
compared with TNF- or IL-1β–medi-
ated induction, indicating distinct 
properties of this ligand when com-
pared with TNF. This kinetic difference 
might be related to the specific activa-
tion of intracellular signaling platforms 
in keratinocytes by these different lig-
ands, which awaits further detailed 
characterization. Emerging evidence 
indicates that death receptors such as 
CD95 activate inflammatory or pro-
liferative signaling via the prototypic 
proinflammatory transcription factor 
NF-κB or the mitogen-activated pro-
tein kinase (MAPK) family of kinases 
(Wajant et al., 2003). Farley and col-
leagues (2006) have tested the con-
tribution of NF-κB and could clearly 
demonstrate the partial or complete 
NF-κB dependence of CD95L-medi-
ated proinflammatory gene activation 
using transient small interfering RNA 
(siRNA) transfection for p65/RelA, in line 
with data using dominant-negative inhi-
bition of the NF-κB pathway employed 
for the study of TRAIL-dependent gene 
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|Only single keratinocytes undergo apoptosis in acute 
eczema.
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induction (Leverkus et al., 2003b). It is 
notable that many tissues, such as the 
skin, express death receptors without 
evidence of extensive apoptosis, signi-
fying that blockade of the death path-
way may be the rule rather than the 
exception under physiological condi-
tions. Although detailed knowledge 
is available about the signaling capa-
bilities and the requirement for adaptor 
molecules such as Fas-associated death 
domain (FADD), the initiator caspase-
8, and its intracellular inhibitor cellu-
lar Flice/Caspase-8 inhibitory protein 
(cFLIP) (Krueger et al., 2001; Thome 
and Tschopp, 2001), physiological and 
pathophysiological evidence for the 
relevance of CD95 signaling pathways 
in the human skin is still sparse (Wehrli 
et al., 2000). Adding to the complexity, 
keratinocytes can themselves augment 
inflammatory and apoptotic responses 
by the production of CD95L, although 
the ligand appears to be intracellu-
larly stored under physiological con-
ditions (Viard-Leveugle et al., 2003). 
Intriguingly, Farley et al. (2006) show 
that CD95L also induces secondary 
cytokines that are subsequently able to 
augment the following inflammatory 
response in keratinocytes, defining an 
autoactivating loop of cytokines in the 
epidermis. Thus CD95 (or other death 
receptors) may have broader function 
in the skin than previously suspected 
and may act as a potential starting 
point of further cutaneous inflamma-
tion (Figure 1).
How can the potentially harmful 
release of CD95L be limited to areas 
of the body where CD95 signaling is 
needed? Farley et al. (2006) made use 
of an elegant fusion protein of CD95L 
that allows for controlled oligomeriza-
tion of the ligand itself. In keratinocytes, 
ligation of CD95L with its receptor 
CD95 is required for inflammatory sig-
nals. Hexameric oligomerized CD95L 
ligates, whereas solely trimeric CD95L 
does not. This may support the hypothe-
sis that mainly membrane-bound forms 
of the ligands, or, alternatively, tissue-
specific aggregation of soluble trimeric 
ligands, is able to signal for apoptosis or 
inflammation depending on the intra-
cellular molecular context of keratino-
cytes. This differential response pattern 
may ensure that upon CD95L induction 
its action may be restricted to regions 
of cell–cell contact or to particular tis-
sue conditions favoring aggregation 
of soluble ligands. The most widely 
studied intracellular signal activated 
by death receptors is the regulated 
activation of a cascade of proteases 
named caspases. Their activity appears 
to be mainly involved in the apoptotic 
response; their importance for non-
apoptotic signals is less well charac-
terized (Lavrik et al., 2005). In order 
to dissect apoptotic and nonapoptotic 
signals, the authors went on to study 
the dependence of proinflammatory 
gene expression of caspase activity 
by using different caspase inhibitors. 
Importantly, the presence of these 
caspase inhibitors efficiently blocked 
the execution of the death program 
but did not suppress proinflammatory 
gene expression, thereby indicating 
that these CD95-mediated signals are 
not a mere epiphenomenon of cellu-
lar apoptosis of keratinocytes. Finally, 
Farley and colleagues (2006) extended 
their study to E6/E7-transformed kerati-
nocytes in a reconstructed skin equiva-
lent that gratifyingly recapitulated their 
findings with HaCaT keratinocytes and 
underlined the potential relevance of 
their findings in vivo. In this context, 
one has to bear in mind that investiga-
tions in mouse models carrying muta-
tions or deficiencies of these signaling 
pathways have their experimental limi-
tations, in particular for the epidermal 
effector phase of eczema, because the 
epidermis of mice does not develop 
the typical features (for example, spon-
giosis, acanthosis, and parakeratosis) of 
human eczematous inflammation.
Figure 1. The skin-selective homing of T cells, their effector functions in the skin, and the differential 
fate of CD95-mediated signals in epidermal keratinocytes as sequential events in the pathogenesis of 
eczematous dermatitis. (a) Accumulation of T cells in the upper dermis during eczematous dermatitis. 
The infiltrate consists predominantly of activated effector T cells that secrete soluble proinflammatory 
molecules (IFN-γ, tumor necrosis factor (TNF)) and express CD95L, CLA, and CD45RO. In the process 
of directed migration, T cells penetrate the basal membrane and reach the epidermis. (b) Epidermal 
keratinocytes may act as enhancers of the eczematous inflammation through nonapoptotic CD95-
triggered signaling and NF-κB- and mitogen-activated protein kinase (MAPK)-controlled expression 
and secretion of proinflammatory cytokines/chemokines that may attract further cellular infiltration. 
(c) CD95-mediated apoptosis of single keratinocytes characterizes the epidermis as a target of 
the proapoptotic response in eczema and may act as a mechanism to remove cells with further 
proinflammatory signaling properties. CD95 apoptosis resistance of epidermal keratinocytes may thus 
critically shape the epidermal outcome of T-cell infiltration by activating either further inflammatory 
cytokines (b) or removal of these keratinocytes by apoptosis (c).
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A variety of important scientific 
issues arise from the data of Farley and 
colleagues (2006). Is CD95L an ini-
tial activator, or rather an amplifier of 
inflammation? If caspase activity is not 
required for CD95-mediated nonapop-
totic signals, are there conditions that 
allow for or block caspase activation in 
the absence of apoptosis? This regulat-
ed caspase activity may potentially be 
crucial for the proinflammatory signal 
by CD95. In contrast to the findings by 
Farley et al. (2006) with pharmacologi-
cal peptide inhibitors of caspases, the 
physiological inhibitor cFLIP appears to 
inhibit death receptor-mediated NF-κB 
activation and gene induction (Kreuz 
et al., 2004; Wachter et al., 2004). These 
variations hint at substantially different 
outcomes of CD95 receptor trigger-
ing depending on the type of inhibitor 
used. Moreover, it could be envisioned 
that physiological regulation of cFLIP 
might be highly relevant to intracellu-
lar signal deviation upon CD95 trigger-
ing. Likewise, intracellular inhibition 
of effector caspases or mitochondrial 
signaling pathways of apoptosis down-
stream of caspase-8 activation by Bcl-2 
family members or inhibitor-of-apop-
tosis proteins (IAPs) (Cory et al., 2003; 
Vaux and Silke, 2005) might inter-
fere with apoptotic, but not nonapop-
totic, signals by death receptors. This 
scenario may ultimately result in an 
uncontrolled activation of CD95-medi-
ated inflammation in the skin, but this 
hypothesis awaits further experimental 
studies. Taken together, it appears that 
CD95 is not only needed for a silent 
end of the life of keratinocytes during 
eczema but may rather contribute to 
a “going out with an (inflammatory) 
bang.” It will be interesting to deter-
mine under which conditions apoptosis 
may predominate over CD95-mediated 
inflammation in keratinocytes. This dif-
ference — subtle at first glance — of a 
death receptor-mediated signal might 
prove to be highly relevant to the quan-
titative response in the skin as the target 
organ of eczematous inflammation.
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The New Keratin Nomenclature
Rebecca M. Porter1
When the first nomenclature of the keratin protein family was published over 
20 years ago, only 19 keratins were thought to exist. Sequencing of the human 
genome has now revealed that there are 54 keratin genes. As a consequence, 
the nomenclature needed revision to apply a logical numbering system that 
includes the more recently identified keratins of the hair follicle.
Journal of Investigative Dermatology (2006) 126, 2366–2368. doi:10.1038/sj.jid.5700532
The intermediate filaments of the cyto-
skeleton in epithelial cells are made up 
of a wide variety of subtly different kera-
tin proteins. Antibodies to keratins have 
been extensively used in dermatology 
research. They are useful tools to defini-
tively identify the many different epithe-
lial cell types of the epidermis and hair 
follicle as well as to determine their dif-
ferentiation state.
The first nomenclature of keratins was 
published 24 years ago by Moll et al. 
(1982). At this time the concept of there 
being two types of keratin proteins, type I 
1Department of Dermatology, Wales College of Medicine, Cardiff University, United Kingdom
Correspondence: Dr. Rebecca M. Porter, Department of Dermatology, Wales College of Medicine, 
Cardiff University, Heath Park, Cardiff CF14 4XN, Wales, United Kingdom. E-mail: porterrm@cf.ac.uk
